Luisana Sisca

Via Alvaro Del Portillo 200
Rome, 00128, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2026

Artificial intelligence for bone metastases: a systematic review and meta-analysis of diagnostic and prognostic performance.

Artificial intelligence for bone metastases: a systematic review and meta-analysis of diagnostic and prognostic performance.

Journal: Frontiers in oncology

Published: June 22, 2026

Skeletal metastatic burden as a strong prognostic factor of survival in advanced NSCLC treated with chemo-immunotherapy: An exploratory imaging-based analysis.

Skeletal metastatic burden as a strong prognostic factor of survival in advanced NSCLC treated with chemo-immunotherapy: An exploratory imaging-based analysis.

Journal: Journal of bone oncology

Published: June 18, 2026

Impact of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy on pCR and Tumor Downstaging in Resectable Gastric Cancer: A Meta-Analysis.

Impact of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy on pCR and Tumor Downstaging in Resectable Gastric Cancer: A Meta-Analysis.

Journal: Cancers

Published: May 30, 2026

Metachronous Multifocal Extradigital Glomus Tumor of Lower Extremity: A Case Report and Literature Review.

Metachronous Multifocal Extradigital Glomus Tumor of Lower Extremity: A Case Report and Literature Review.

Journal: Case reports in orthopedics

Published: May 11, 2026

Toxicities of Antibody-Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management.

Toxicities of Antibody-Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management.

Journal: Pharmaceutics

Published: May 05, 2026

Artificial intelligence-enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications.

Artificial intelligence-enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications.

Journal: Frontiers in oncology

Published: April 08, 2026

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

Journal: NPJ breast cancer

Published: March 09, 2026

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Journal: Cancer treatment reviews

Published: March 06, 2026

Impact of Local Treatment of the Primary Tumor on Overall Survival in De Novo Metastatic Breast Cancer: A Systematic Review and Meta-analysis.

Impact of Local Treatment of the Primary Tumor on Overall Survival in De Novo Metastatic Breast Cancer: A Systematic Review and Meta-analysis.

Journal: Cancer diagnosis & prognosis

Published: February 18, 2026

Circulating Tumor Cells: Isolation, Preclinical Models, and Clinical Applications for Personalized Cancer Therapy.

Circulating Tumor Cells: Isolation, Preclinical Models, and Clinical Applications for Personalized Cancer Therapy.

Journal: Biomolecules

Published: February 04, 2026

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 23, 2025

Showing 1-12 of 19

Last Updated: 09/26/2026